Androgen Therapy in Women
- PMID: 31687883
- DOI: 10.1089/jwh.2018.7494
Androgen Therapy in Women
Erratum in
-
Correction to: Androgen Therapy in Women, by Vegunta, S. et al. J Women's Health 2020;29(1):57-64. DOI: 10.1089/jwh.2018.7494.J Womens Health (Larchmt). 2020 Nov;29(11):1487. doi: 10.1089/jwh.2018.7494.correx. J Womens Health (Larchmt). 2020. PMID: 33196333 Free PMC article. No abstract available.
Abstract
Androgens are believed to have an important biologic role in women, particularly in regulation of libido and sexual arousal, although much about their function on other systems in women is unknown. Testosterone, the primary ovarian androgen, has been used to treat carefully selected postmenopausal women with hypoactive sexual desire disorder (HSDD). However, testosterone use in women has not been approved by the United States Food and Drug Administration (FDA) because of uncertainties regarding the effectiveness and long-term safety of this strategy. An intravaginal form of the adrenal androgen, dehydroepiandrosterone (DHEA) has been approved by the FDA to treat genitourinary syndrome of menopause. In this article, we review the current knowledge regarding the role of androgens and their clinical use in women. We conducted a systematic search of PubMed for publications describing the role and clinical use of androgens in women. We used the search terms "HSDD," "DHEA in women," "testosterone in women," and "androgens in women," and reviewed most references from all relevant articles. Most randomized placebo-controlled trials show an improvement in sexual function with low-dose testosterone therapy in select postmenopausal women with HSDD. Although this strategy appears to be safe in the short term and no major safety concerns have emerged thus far, long-term effects on cardiovascular risk and breast cancer incidence are not known. A trial of low-dose testosterone therapy may be considered for carefully selected postmenopausal women with HSDD, as long as other contributors to sexual dysfunction have been adequately addressed. However, patients need careful counseling regarding the lack of long-term safety data, and close clinical and laboratory monitoring of these women is recommended to avoid supraphysiologic dosing.
Keywords: hormone replacement therapy; menopause.
Similar articles
-
The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.Maturitas. 2009 Jul 20;63(3):213-9. doi: 10.1016/j.maturitas.2009.04.008. Epub 2009 May 31. Maturitas. 2009. PMID: 19487090 Review.
-
A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder.Am Heart J. 2012 Jan;163(1):27-32. doi: 10.1016/j.ahj.2011.09.021. Epub 2011 Nov 21. Am Heart J. 2012. PMID: 22172433 Clinical Trial.
-
The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.J Sex Med. 2008 Sep 2;5 Suppl 4:182-93; quiz 193. doi: 10.1111/j.1743-6109.2008.00961.x. J Sex Med. 2008. PMID: 18783534 Review.
-
The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review.Int J Impot Res. 2022 Nov;34(7):635-641. doi: 10.1038/s41443-022-00613-0. Epub 2022 Oct 5. Int J Impot Res. 2022. PMID: 36198811 Free PMC article. Review.
-
[The Role of Testosterone in The Improvement of Sexual Desire in Postmenopausal Women: An Evidence-Based Clinical Review].Acta Med Port. 2018 Nov 30;31(11):680-690. doi: 10.20344/amp.9277. Epub 2018 Nov 30. Acta Med Port. 2018. PMID: 30521462 Review. Portuguese.
Cited by
-
Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.BMC Womens Health. 2024 Mar 8;24(1):167. doi: 10.1186/s12905-024-02990-8. BMC Womens Health. 2024. PMID: 38459552 Free PMC article. Clinical Trial.
-
Gender Dysphoria and Sexual Euphoria: A Bayesian Perspective on the Influence of Gender-Affirming Hormone Therapy on Sexual Arousal.Arch Sex Behav. 2024 May;53(5):1859-1871. doi: 10.1007/s10508-023-02778-1. Epub 2024 Jan 12. Arch Sex Behav. 2024. PMID: 38216784 Free PMC article.
-
New Possibilities for Hormonal Vaginal Treatment in Menopausal Women.J Clin Med. 2023 Jul 18;12(14):4740. doi: 10.3390/jcm12144740. J Clin Med. 2023. PMID: 37510854 Free PMC article. Review.
-
Effects of testosterone treatment on anal sphincter damage repair in ovariectomized rats.Turk J Med Sci. 2023 Apr;53(2):475-485. doi: 10.55730/1300-0144.5607. Epub 2023 Apr 19. Turk J Med Sci. 2023. PMID: 37476872 Free PMC article.
-
What Role do Androgens Play in Endometrial Cancer?J Pers Med. 2023 Feb 16;13(2):341. doi: 10.3390/jpm13020341. J Pers Med. 2023. PMID: 36836575 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical